|
TAM (n = 240)
|
TOR (n = 212)
|
P value
|
---|
Age
| | |
0.552
|
18-34
|
34
|
26
| |
>35
|
206
|
186
| |
T
| | |
0.744
|
1
|
147
|
137
| |
2
|
84
|
67
| |
3
|
9
|
8
| |
N
| | |
0.536
|
0
|
142
|
136
| |
1-3
|
61
|
52
| |
4-9
|
27
|
19
| |
≥10
|
10
|
5
| |
AJCC Stage
| | |
0.616
|
I
|
98
|
97
| |
IIA
|
70
|
64
| |
IIB
|
32
|
25
| |
IIIA
|
30
|
21
| |
IIIB
|
0
|
0
| |
IIIC
|
10
|
5
| |
HER-2 status
| | |
0.359
|
Positive
|
37
|
23
| |
Negative
|
148
|
137
| |
Unknown
|
55
|
52
| |
Grade
| | |
0.328
|
I
|
51
|
37
| |
II
|
141
|
120
| |
III
|
47
|
52
|
0.530
|
Unknown
|
1
|
3
| |
Risk of recurrence
| | |
0.313
|
Low
|
11
|
15
| |
Intermediate or
|
229
|
197
| |
high
| | |
0.024
|
Local control
|
117
|
130
| |
BCS + RT
|
90
|
57
| |
Modified
|
33
|
25
| |
Modified + RT
| | |
0.513
|
Chemotherapy
|
15
|
10
| |
CMF
|
96
|
92
| |
ET
|
62
|
42
| |
FEC
|
43
|
45
| |
TC
|
24
|
23
| |
No chemotherapy
| | | |
- Differences between the two groups were evaluated using a χ2 test.